TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

NCT04490694 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
PROCEDURE: TACE

Sponsor

Shanghai Zhongshan Hospital